MEIP MEI Pharma Inc
8,287
$3.20
$0.14
(4.58%)
| Watchers | 8,287 |
| 52-Wk Low | $3.01 |
| 52-Wk High | $6.91 |
| Market Cap | $20.39M |
| Volume | 15,179.00 |
| 52-Wk High | $6.91 |
| 52-Wk Low | $3.01 |
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344Business Wire • 25 days ago
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported...
Share to Feed
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported...
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced...
MEI Pharma, Inc. (NASDAQ:MEIP Get Free Report) saw a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 9,100 shares, a...
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported...
MEI Pharma files for $100M mixed shelf...
StockNews.com downgraded shares of MEI Pharma (NASDAQ:MEIP Free Report) from a buy rating to a hold rating in a report released on Tuesday morning. Separately, TheStreet downgraded MEI Pharma...
MEI Pharma (NASDAQ:MEIP Get Free Report) had its target price reduced by investment analysts at Stifel Nicolaus from $8.00 to $7.00 in a research note issued to investors on Wednesday...
Glancy Prongay & Murray LLP (GPM) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors and officers possible violations of state laws. If you own...
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported...